



TEXAS
Health and Human
Services

**Texas Department of State
Health Services**

Texas Vaccine Providers Webinar

Tuesday, April 5th, 2022

Disclaimer

The information presented today is based on CDC's recent guidance and MAY change.

Tuesday, April 5th, 2022

Discussion Topics

Opening Remarks – Tony Aragon, MS

COVID-19 Vaccine Updates – Saroj Rai, PhD, MPH

COVID-19 Vaccine Clinical Reminders – Cheryl Garcia, BSN, RN

COVID-19 Vaccine Product Ordering Updates – Oscar Paz

Live Q&A



Texas Department of State
Health Services

Opening Remarks

Tony Aragon, MS

Director | Immunization Unit

COVID-19 Vaccine Updates

Saroj Rai, PhD, MPH

Senior Scientific Advisor | Office of Chief State Epidemiologist

Terminology for COVID-19 Vaccine Dosing

Primary series:

- For most people, a 2-dose series of an mRNA COVID-19 vaccine (Pfizer-BioNTech and Moderna) or a single dose of Janssen COVID-19 Vaccine.
- For people who are moderately or severely immunocompromised, a 3-dose series of an mRNA COVID-19 vaccine or a single dose of Janssen COVID-19 Vaccine.

Additional dose: A subsequent dose of vaccine administered to people who were less likely to mount a protective immune response after initial vaccination. People who are moderately or severely immunocompromised and who received Janssen COVID-19 Vaccine for their primary series should receive an additional dose.

Booster dose: A subsequent dose of vaccine administered to enhance or restore protection which might have waned over time after primary series vaccination.

- **Homologous booster dose:** The same vaccine product used for the booster dose was administered for the primary series.
- **Heterologous booster dose (mix-and-match booster):** The vaccine product used for the booster dose differs from the product administered for the primary series.

Up to date: A person has received all recommended doses in their primary vaccine series, and a booster dose, when eligible. **Receipt of a second booster dose is not necessary to be considered up to date at this time.**

COVID-19 Vaccines Approved or Authorized in the United States

March 29, 2022

March 29, 2022	Age Indication	Vaccine Vial Cap Color	Dilution Required	Primary Series		Booster Dose ^b	
				Dose	Injection Volume	Dose	Injection Volume
Pfizer	5 – 11 years	Orange	Yes	10 mcg	0.2 mL ^a	NA	NA
Pfizer	≥ 12 years	Purple	Yes	30 mcg	0.3 mL	30 mcg	0.3 mL
Pfizer	≥ 12 years	Gray	No	30 mcg	0.3 mL	30 mcg	0.3 mL
Moderna	≥ 18 years	Red ^d	No	100 mcg	0.5 mL	50 mcg	0.25 mL
Moderna	≥ 18 years	Blue^d	No	NA	NA	50 mcg	0.5 mL
J&J's Janssen ^c	≥ 18 years	Blue	No	5×10 ¹⁰ viral particles	0.5 mL	5×10 ¹⁰ viral particles	0.5 mL

a: Dose based on age at the time of the vaccination

b: Booster doses may be mix and match for individuals ≥18 yrs, mRNA vaccines are preferred : [Booster dose may be mix-and-match vaccine](#)

c: [mRNA COVID-19 vaccines are preferred over the J&J COVID-19 vaccine](#)

d: Either Moderna COVID-19 Vaccine supplied in a vial with a red cap (0.25 mL injection volume) or Moderna COVID-19 Vaccine supplied in a vial with a blue cap (0.5 mL injection volume) can be used to administer a 50 mcg booster dose.

March 29, 2022	COVID-19 Vaccination Schedule for People Who are NOT Moderately or Severely Immunocompromised			
	Number of Doses in Primary Series	Number of Booster Doses	Interval between 1 st Dose and 2 nd Dose	Interval between 2 nd Dose and Booster Dose ^b
Pfizer (5-11 years) (orange cap)	2	NA	3 weeks	NA
Pfizer (≥12 years) (purple → gray cap)	2	1 ^d	3-8 weeks ^a	≥ 5 months ^d
Moderna (≥18 years)	2	1 ^d	4-8 weeks ^a	≥ 5 months ^d
J&J's Janssen (≥18 years) ^c	1	1 ^d	NA	≥ 2 months ^d (between dose 1 and booster dose)

a: An **8-week** interval may be optimal for some people ages 12 years and older, especially **for males ages 12 to 39 years**. A **shorter interval** (3 weeks for Pfizer; 4 weeks for Moderna) between the first and second doses remains the recommended interval for: people who are moderately to severely immunocompromised; adults ages 65 years and older; and others who need rapid protection due to increased concern about community transmission or risk of severe disease: [COVID-19 vaccination schedule for the primary series in the general population](#)

b: Booster doses may be mix and match for individuals ≥18 yrs, mRNA vaccines are preferred : [Booster dose may be mix-and-match vaccine](#)

c: [mRNA COVID-19 vaccines are preferred over the J&J COVID-19 vaccine](#)

- d.** All people ages 12 years and older should receive 1 booster dose of a COVID-19 vaccine. Some adults may receive a second booster dose:
- Adults ages 18-49 years: Those who received Janssen COVID-19 Vaccine as both their primary series dose and booster dose may receive an mRNA COVID-19 booster dose at least 4 months after the Janssen booster dose.
 - Adults ages 50 years and older: A second mRNA booster dose could benefit people ages 50 years and older, as they are at increased risk for severe COVID-19. People ages 50 years and older may choose to receive a second booster dose, if it has been at least 4 months after the first booster.

COVID-19 vaccination schedule for people who are NOT moderately or severely immunocompromised

COVID-19 Vaccine	0 month	1 month	2 month	3 month	4 month	5 month	6 month	7 month	8 month	9 month	10 month	11 month
Pfizer (5-11 yrs) (orange cap)	1 st dose	2 nd dose										
Pfizer (≥12 yrs) (purple → gray cap)	1 st dose	2 nd dose (3-8 weeks after 1 st dose)					Booster dose (at least 5 months after 2 nd dose)				§ (≥50 yrs)	
Moderna (≥18 yrs)	1 st dose	2 nd dose (4-8 weeks after 1 st dose)					Booster dose (at least 5 months after 2 nd dose)				§ (≥50 yrs)	
J&J's Janssen (≥18 yrs)	1 st dose			Booster dose			§ (18-49 yrs)					

§ People ages 50 years and older may choose to receive a second booster dose if it has been at least 4 months after the first booster dose.

§ People ages 18–49 years who received Janssen COVID-19 Vaccine as both their primary series dose and booster dose may receive an mRNA COVID-19 booster dose at least 4 months after the Janssen booster dose.

March 29, 2022	COVID-19 Vaccination Schedule for People Who ARE Moderately or Severely Immunocompromised				
	Number of Doses in Primary Series	Number of Booster Doses	Interval between 1 st Dose and 2 nd Dose	Interval between 2 nd dose and 3 rd Dose	Interval between 3 rd Dose and 1st Booster dose ^a
Pfizer (5-11 years) (orange cap)	3	NA	3 weeks	≥ 4 weeks	NA
Pfizer (≥12 years) (purple → gray cap)	3	1 ^c	3 weeks	≥ 4 weeks	≥ 3 months ^c
Moderna (≥18 years)	3	1 ^c	4 weeks	≥ 4 weeks	≥ 3 months ^c
J&J's Janssen (≥18 years) ^b	1 Dose Janssen, followed by 1 Dose of mRNA vaccine	1 ^c	4 weeks	≥ 2 months	NA ^c

a: Booster doses may be mix and match for individuals ≥18 yrs, mRNA vaccines are preferred : [Booster dose may be mix-and-match vaccine](#)

b: [mRNA COVID-19 vaccines are preferred over the J&J COVID-19 vaccine](#)

C: People ages 12 years and older may choose to receive a second booster dose using an mRNA COVID-19 vaccine if it has been at least 4 months after the first booster dose.

COVID-19 vaccination schedule for people who ARE Moderately or Severely Immunocompromised

COVID-19 Vaccine	0 month		1 month		2 month		3 month		4 month		5 month		6 month		7 month		8 month		9 months	
Pfizer (5-11 yrs) (orange cap)	1 st dose		2 nd dose		3 rd dose															
Pfizer (≥12 yrs) (purple → gray cap)	1 st dose		2 nd dose		3 rd dose						Booster dose								§	
Moderna (≥18 yrs)	1 st dose		2 nd dose		3 rd dose						Booster dose								§	
J&J's Janssen (≥18 yrs)	1 st dose		2 nd dose with an mRNA Vx					Booster dose									§			

§ People ages 12 years and older may choose to receive a second booster dose using an mRNA COVID-19 vaccine if it has been at least 4 months after the first booster dose. For people ages 12–17 years, only Pfizer-BioNTech can be used.

Appendix D. Schedule guidance for people who are moderately or severely immunocompromised

D1. People who are moderately or severely immunocompromised and **initiate a Janssen COVID-19 Vaccine primary series**

March 29, 2022

COVID-19 vaccination history	And	Then	Next dose due
1 dose	The dose was Janssen COVID-19 Vaccine	Administer a second (additional) dose using an mRNA vaccine at least 28 days after the 1st dose. <ul style="list-style-type: none"> • Pfizer: 0.3mL, or • Moderna 0.5mL (red cap) 	Administer a booster dose at least 2 months after the 2nd dose.*† <ul style="list-style-type: none"> • Pfizer: 0.3mL, or • Moderna: 0.25mL (red cap) or 0.5 mL (blue cap), or • Janssen: 0.5mL (mRNA is preferred over Janssen)
2 doses	Both doses are Janssen COVID-19 Vaccine	Administer a third (additional) dose using an mRNA vaccine at least 2 months after the 2nd dose. <ul style="list-style-type: none"> • Pfizer: 0.3mL, or • Moderna: 0.5mL (red cap) 	No additional vaccinations needed.†
	1 dose of Janssen COVID-19 Vaccine and 1 dose of an mRNA COVID-19 vaccine (given as booster dose, i.e., Pfizer 0.3mL or Moderna 0.25mL [red cap], or Moderna 0.5mL [blue cap]) ‡	Administer a third (additional) dose using an mRNA vaccine at least 2 months after the 2nd dose. <ul style="list-style-type: none"> • Pfizer: 0.3mL, or • Moderna: 0.5mL (red cap) 	No additional vaccinations needed.†
	1 dose of Janssen COVID-19 Vaccine and 1 dose of an mRNA COVID-19 vaccine (given as additional dose, i.e., Pfizer 0.3mL or Moderna 0.5mL [red cap]) ‡	Administer a booster dose of any COVID-19 vaccine 2 months after the 2nd dose. <ul style="list-style-type: none"> • Pfizer: 0.3mL, or • Moderna: 0.25mL (red cap) or 0.5mL (blue cap), or • Janssen: 0.5mL (mRNA is preferred over Janssen) 	No additional vaccinations needed.†

[CDC Interim Clinical Considerations](#)

*mRNA vaccines are preferred.

† See guidance on [booster doses for people who are moderately or severely immunocompromised](#) for information on the option of a second booster dose for some people.

‡ When reviewing vaccination history, doses of the Moderna COVID-19 Vaccine received prior to February 7, 2022 should be considered to have been the booster dosage (0.25 mL; 50 µg).

Appendix D. Schedule guidance for people who are moderately or severely immunocompromised

D2. People who are moderately or severely immunocompromised and **initiate an mRNA COVID-19 vaccine primary series**

March 29, 2022

COVID-19 vaccination history	And	Then	Next dose due
1 dose	The dose was an mRNA vaccine	Administer a second primary series dose of the same mRNA vaccine <ul style="list-style-type: none"> 3 weeks after the first dose, if Pfizer-BioNTech 4 weeks after the first dose, if Moderna 	Administer a third primary series dose of the same mRNA vaccine at least 4 weeks after the second dose. Then, administer a booster dose at least 3 months after the third dose.*†
2 doses	The 2 doses are the same mRNA vaccine (both Pfizer-BioNTech or both Moderna)	Administer a third primary series dose of the same mRNA vaccine at least 28 days after the second dose.	Administer a booster dose at least 3 months after the third primary series dose.*†
	The 2 doses are different mRNA vaccines (1 dose Pfizer-BioNTech and 1 dose Moderna)	Administer a third primary series dose of either mRNA vaccine at least 28 days after the second dose.	Administer a booster dose at least 3 months after the third primary series dose.*†
	The 2 doses are different types of vaccines (1 dose of an mRNA vaccine and 1 dose of Janssen)	This is considered a Janssen COVID-19 Vaccine primary series. Administer an additional dose of Pfizer-BioNTech or Moderna at least 28 days after the Janssen COVID-19 Vaccine.	Administer a booster dose at least 2 months after the additional mRNA vaccine dose.*†
3 doses	3 primary series doses of an mRNA vaccine (includes 3 doses of the same mRNA vaccine or a mixed mRNA vaccine series)	Administer a booster dose of any vaccine (mRNA preferred) at least 3 months after the last dose given. <ul style="list-style-type: none"> Pfizer: 0.3 mL, or Moderna 0.25 mL (red cap) or 0.5 mL (blue cap), or Janssen: 0.5 mL (mRNA is preferred over Janssen) 	No additional vaccinations needed.†
	2 primary series doses of an mRNA vaccine and 1 booster dose of any vaccine	Administer a fourth dose of an mRNA vaccine at least 3 months after the last dose given. <ul style="list-style-type: none"> Pfizer: 0.3 mL, or Moderna 0.5 mL (red cap) 	No additional vaccinations needed.†

*mRNA vaccines are preferred.

† See guidance on booster doses for [people who are moderately or severely immunocompromised](#) for information on the option of a second booster dose for some people.

COVID-19 Vaccine Clinical Reminders

Cheryl Garcia, BSN, RN

Contract Nurse III | Immunization Unit

COVID-19 Provider Best Practices

- EUA Fact Sheet Update
- Storage & Handling of COVID-19 Vaccines



CDC COVID-19 Vaccine Information Fact Sheet

As per your provider agreement, organizations must provide an approved Emergency Use Authorization (EUA) fact sheet or vaccine information statement (VIS), to each vaccine recipient, the adult caregiver accompanying the recipient, or other legal representative before administering COVID-19 Vaccine.

Please click the link below to review the updated COVID-19 EUA Fact Sheets for Recipients and Caregivers:

[COVID-19 Vaccine EUA Recipient/Caregiver Fact Sheets | CDC](https://www.cdc.gov/vaccines/imz/downloads/#COVID-19)

VACCINE INFORMATION FACT SHEET FOR RECIPIENTS AND CAREGIVERS ABOUT SPIKEVAX (COVID-19 VACCINE, mRNA) AND THE MODERNA COVID-19 VACCINE TO PREVENT CORONAVIRUS DISEASE 2019 (COVID-19) IN INDIVIDUALS 18 YEARS OF AGE AND OLDER

You are being offered either SPIKEVAX (COVID-19 Vaccine, mRNA) or the Moderna COVID-19 Vaccine to prevent Coronavirus Disease 2019 (COVID-19) caused by SARS-CoV-2.

This Vaccine Information Fact Sheet for Recipients and Caregivers comprises the Fact Sheet for the authorized Moderna COVID-19 Vaccine and also includes information about the FDA-licensed vaccine, SPIKEVAX (COVID-19 Vaccine, mRNA) for use in individuals 18 years of age and older.


The FDA-approved SPIKEVAX (COVID-19 Vaccine, mRNA) and the Moderna COVID-19 Vaccine authorized for Emergency Use Authorization (EUA) for individuals 18 years of age and older can be used interchangeably, when used according to their respective instructions for use.¹




SPIKEVAX (COVID-19 Vaccine, mRNA) is an FDA-approved COVID-19 vaccine made by ModernaTX, Inc. It is approved as a two-dose series for prevention of COVID-19 in individuals 18 years of age and older. It is also authorized under EUA to provide:

- a third primary series dose to individuals 18 years of age and older who have been determined to have certain kinds of immunocompromise;
- a first booster dose to individuals 18 years of age and older who have completed a primary series with Moderna COVID-19 Vaccine or SPIKEVAX (COVID-19 Vaccine, mRNA);
- a first booster dose to individuals 18 years of age and older who have completed primary vaccination with another authorized or approved COVID-19 vaccine. The booster schedule is based on the labeling information of the vaccine used for the primary series;
- a second booster dose to individuals 50 years of age and older who have received a first booster dose of any authorized or approved COVID-19 vaccine; and
- a second booster dose to individuals 18 years of age and older with certain kinds of immunocompromise and who have received a first booster dose of any authorized or approved COVID-19 vaccine.

¹ FDA-approved SPIKEVAX (COVID-19 Vaccine, mRNA) and one presentation of the EUA-authorized Moderna COVID-19 Vaccine (supplied in vials with red caps) can be used interchangeably for the primary series and booster doses without presenting any safety or effectiveness concerns. One presentation of the Moderna COVID-19 Vaccine (supplied in vials with dark blue caps) is authorized for emergency use to provide booster doses only. The booster dose only presentation of the Moderna COVID-19 Vaccine is not authorized to provide a primary series dose. SPIKEVAX (COVID-19 Vaccine, mRNA) or the two EUA-authorized presentations of Moderna COVID-19 Vaccine (supplied in vials with red caps or vials with dark blue caps) can be used to provide a booster dose(s), and the choice of presentation does not present any safety or effectiveness concerns.



Storage Options for Pfizer COVID-19 Vaccines



	Thermal Shipper	Ultra-Low Freezer	Freezer	Refrigerator	Room Temp.
 <p>Orange Cap 5 through 11 Years</p>	✗	9 months	✗	10 weeks	<p>Undiluted/Unpunctured • Up to 12 hrs.</p> <p>Punctured/Diluted • Discard after 12 hrs.</p>
 <p>Gray Cap 12 Years and Older</p>	✗	9 months	✗	10 weeks	<p>Unpunctured • Up to 12 hrs.</p> <p>Punctured • Discard after 12 hrs.</p>
 <p>Purple Cap 12 Years and Older</p>	30 days^a	9 months	2 weeks	31 days	<p>Undiluted/Unpunctured • Up to 2 hrs.</p> <p>Punctured/Diluted • Discard after 6 hrs.</p>

a: read manufacturer's guidelines for dry ice replacement

Recording dates and times ensure that the vaccine is actively monitored and stored according to the manufacturer's guidelines for viability.

	Ultra-Low Freezer	Refrigerator	Room Temp.
 Gray Cap 12 Years and Older	9 months	10 weeks	Undiluted/Unpunctured • Up to 12 hrs. Punctured/Diluted • Discard after 12 hrs.
 Orange Cap 5 through 11 Years			

- Calculate 9 months out from the Manufacturer's date to obtain the expiration date if you are planning on storing in **Ultra-low** temperature conditions
- Write the date the vial was received on the vaccine. Calculate 10 weeks from the date the vaccine was put in the refrigerator to obtain the beyond use date. Ensure the BUD does not exceed the expiration date calculated.
- Write the time on the vial once it is moved to **Room-Temperature**

Pfizer COVID-19 Vaccine

Manufacture Labels

appetite (0.3%), rash (0.3%), and pain in extremity (0.3%).

THREE VACCINE PRESENTATIONS ARE AVAILABLE

Three vaccine presentations are available with different preparation and storage guidelines.

As of 12/16/21, Ages 12 years and older, DO NOT DILUTE (Gray Cap) and **5 through 11 years, DILUTE BEFORE USE (Orange Cap)** have extended expiry from 6 months to 9 months from the date of manufacture printed on the vial and cartons in an Ultra-Low-Temperature (ULT) Freezer -90°C to -60°C (-130°F to -76°F).

Please see the table below and click the following button for expiry information:

EXPIRY INFORMATION

Children ages 5 through 11 years old should only be vaccinated with the **Ages 5 through 11**

Note: Pfizer gray cap COVID-19 vaccines and Pfizer orange cap COVID-19 vaccines do NOT have an expiration printed on the vial. Instead, each vial has the lot number **and date of manufacture printed on the label.**

For more information, please contact:
pfizermedicalinformation@pfizer.com or **800-438-1985**

Recording dates and times ensure that the vaccine is actively monitored and stored according to the manufacturer's guidelines for viability.

MODERNA	Freezer	Refrigerator	Room Temp.
	Up to the Expiration Date	30 Days	Unpunctured: Up to 24 hours Punctured: Discard after 12 hours *do NOT puncture > 20 times

- When stored in the **Freezer** the vaccine remains viable until the expiration date or until you move the vaccine to a different storage method
- When stored in the **Refrigerator** the vaccine remains viable for 30 days or until punctured or moved
- When stored at **Room Temperature** the vaccine remains viable for 24 hours unpunctured. After puncture, the vaccine must be discarded in 12 hours.

Moderna COVID-19 Vaccine

Expiration Date

For more information, please contact:
excursions@modernatx.com or **866-663-3762**

1. Visit the Moderna website:
<https://www.modernatx.com/covid19vaccine-eua/providers/vial-lookup#vialLookupTool>

How To Look Up Vial Expiration Date

2. Locate the **vaccine lot number** printed on the carton and vial.

To find the expiration for Moderna COVID-19 Vaccine released to the United States Government, locate the lot number, printed on the carton and vial. Enter the lot number in the field below and press "Submit." Please note, this tool is not validated to authenticate or confirm legitimacy of vaccine.

3. Enter the **vaccine lot number** in the box.

4. Select **Submit**.

Enter Lot #

Submit

COVID-19 Vaccine Product Ordering Updates

Oscar Paz

Program Specialist V | Immunization Unit

COVID-19 Provider Inventory Reporting

Mandatory Reporting Coming Due



Reminder to complete survey to verify your current COVID-19 vaccine inventory.

Beginning May 2, 2022, the Texas Department of State Health Services will be requiring all providers to report their current COVID-19 vaccine inventory by vaccine type in VAOS.

In order to verify current COVID-19 vaccine inventory, DSHS will be sending out an inventory survey via email to collect doses of COVID-19 vaccine on hand, by vaccine type.

Providers should only report their current inventory on hand. DO NOT include expired or wasted COVID-19 in the inventory survey.

Check your inbox!



Provider Group	Survey Sent via Email	Survey Due Date
Group 1	Monday, April 4th	Friday, April 8 th @ 5:00pm CST
Group 2	Wednesday, April 6th	Tuesday, April 12 th @ 5:00pm CST

Live Q&A

VacShipments

COVID19VacShipments@dshs.Texas.gov

VacManagement

COVID19VacMgmt@dshs.Texas.gov

VacEnroll

COVID19VacEnroll@dshs.texas.gov

ImmTrac2

ImmTrac2@dshs.Texas.gov
ImmTracMU@dshs.texas.gov (for data exchange)

Nurse Call Center

CoronaVirus@dshs.texas.gov
COVIDvaccineQs@dshs.Texas.gov

Or call (833) 832-7068

Texas Vaccine Providers Webinar Survey

We want to hear from you in our Texas Vaccine Providers **Webinar Survey**! This quick survey helps us create content that is relevant and helpful for our Texas providers week over week.

Please complete our [post webinar survey](#) for the **4/5 Texas Vaccine Providers Webinar** by Wednesday, 4/6 at 5:00pm CT.

DSHS Texas Providers Webinar Survey - April 5, 2022

Were you able to attend the Texas Provider webinar this week?

- ☒ Yes
- ☐ No
- ☐ Partly

Are you a COVID-19 Vaccine Provider?

- ☐ Yes
- ☐ No

Overall the information shared today was helpful.

- ☐ Strongly Agree
- ☐ Agree
- ☐ Neutral
- ☐ Disagree
- ☐ Strongly Disagree

The information was presented clearly.

- ☐ Strongly Agree
- ☐ Agree
- ☐ Neutral
- ☐ Disagree
- ☐ Strongly Disagree

Resources



TEXAS
Health and Human
Services

Texas Department of State
Health Services

Pfizer Medical Affairs-Led Training Events

Goal: Educate providers and immunization staff personnel on the proper use of the Pfizer-BioNTech COVID-19 Vaccine.

Updated Schedule

To access dates and links for upcoming training sessions, please visit:

<https://www.pfizermedicalinformation.com/en-us/medical-updates>

Session topics include:

- *NEW* Introduction of new Controlant Temperature Monitoring Device
- Use of each vaccine presentation, including storage, handling, preparation, and administration for:
 - Ages 5 through 11 Years: **DILUTE BEFORE USE/Orange Cap**
 - Ages 12 Years and Older: **DO NOT DILUTE/Gray Cap; DILUTE BEFORE USE/Purple Cap**
- Recent medical updates regarding the vaccine
- An overview of healthcare provider resources
- Question and answer session

Date & Time	Password
Attendee link – Tuesday, April 5 - 3pm ET	rdPJ3ZKvf49
Attendee link – Wednesday, April 6 - 12pm ET	e3pJQmizR32
Attendee link – Thursday, April 7 - 12pm ET	vbKK2Dbs38j
Attendee link – Tuesday, April 12 - 3pm ET	gaKVvMUP733
Attendee link – Wednesday, April 13 - 12pm ET	mkP722m68GC
Attendee link – Thursday, April 14 - 12pm ET	EGm7DmgpT52
Attendee link – Tuesday, April 19 - 3pm ET	3rYVYBmNX75

Visit Pfizer's webpage for more information about Pfizer led training events: <https://www.pfizermedicalinformation.com/en-us/medical-updates>

COVID-19 Vaccine Product Availability

When you enter the “doses requested,” remember that each COVID-19 vaccine type ships in different pack sizes. Use the table below to determine how many doses to request:

Moderna		Pfizer Adult/Adolescent (12+ yrs)		Pfizer Pediatric (5 -11 yrs)		Janssen/J&J
<100 Doses	>100 Doses	<300 Doses	>300 Doses	<100 Doses	>100 Doses	>100 Doses
Place orders in multiples of 10 doses (1 vial) up to a maximum of 60 doses	Place orders in multiples of 100 doses	Place orders in multiples of 6 doses (1 vial) up to a maximum of 102 doses	Place orders in multiples of 300 doses	Place orders in multiples of 10 doses (1 vial) up to a maximum of 100 doses	Place orders in multiples of 100 doses	Place orders in multiples of 100 doses

Providers placing order requests for more than one COVID-19 vaccine presentation in VAOS will be required to place a *separate order request* for each COVID-19 vaccine presentation they wish to order.

COVID-19 Vaccine Provider Support

Call the COVID-19 Provider Support Help Desk at 833-832-7068

Hours of Operation: Monday to Friday, 8 a.m. - 5 p.m. CT

Category	COVID-19 Vaccine Provider Enrollment (Syntropi)	COVID-19 Vaccine Provider Information and Safety Reporting	Vaccine Allocation & Ordering System (VAOS)	Vaccine Distribution & Shipments	Reporting for COVID-19 Vaccines
Sample questions	<ul style="list-style-type: none"> How to become a COVID-19 Vaccine Provider In-progress applications Update Enrollment accounts, including population numbers, email addresses, or primary/backup coordinators 	<ul style="list-style-type: none"> COVID-19 vaccine safety & medical info Administration of vaccine Reporting adverse events to VAERS Questions/concerns for clinical vaccine considerations 	<ul style="list-style-type: none"> Access to VAOS Question about completing a task or process in VAOS or dashboards Provider Webinars 	<ul style="list-style-type: none"> Tracking shipments Orders Vaccine transfer Waste disposal Changing inventory in VAOS 	<ul style="list-style-type: none"> Reporting to ImmTrac2 via online web application
Provider Support Channel	Provider Help Desk: (833) 832-7068 (Option 1) or (877) 835-7750 or Email: COVID19VacEnroll@dshs.texas.gov HealthCare Providers/Professionals https://www.cdc.gov/vaccines/hcp/index.html	COVID-19 Nurse Call Center: (833) 832-7068 (Option 4) or Texas 2-1-1 (Option 6), 8 a.m. to 5 p.m., Monday through Friday or Email: CoronaVirus@dshs.texas.gov General Immunization Questions: COVIDvaccineQs@dshs.texas.gov	Covid-19 Vaccine Management: (833) 832-7068 (Option 2) or Email: COVID19VacMgmt@dshs.texas.gov	Vaccine Shipments: (833) 832-7068 (Option 2) or Email: COVID19VacShipments@dshs.texas.gov For questions about COVID-19 vaccine storage/handling, refer to the manufacturer resources .	ImmTrac2 team: (833) 832-7068 (Option 3) or (800) 348-9158, 8 a.m. to 4:30 p.m., Monday through Friday or Email: ImmTrac2@dshs.texas.gov ImmTracMU for Data Exchange: 800-348-9158 or Email: ImmTracMU@dshs.texas.gov
Include in email:	Current and new vaccine coordinator name and email address (if new coordinators requested)		Provider name, org code, and primary and backup vaccine coordinator names and email addresses	Provider name, org code, and service request number or shipment number	

Identification, Disposal, and Reporting of COVID-19 Vaccine Waste

The Operational Summary for the identification, disposal, and reporting of waste has been developed into a webpage for jurisdictions and providers. This page provides information to help awardees and immunization managers identify, handle, dispose of, and report waste in **COVID-19 vaccination programs**. This waste management guidance should not be used for non-COVID-19 vaccines, which are covered under other Centers for Disease Control and Prevention (CDC) vaccination programs. The webpage can be found at the link below:

<https://www.cdc.gov/vaccines/covid-19/hcp/wastage-operational-summary.html>

COVID-19 Vaccine Waste Guidance

Waste Disposal and Reporting Resources

While it is important to try to use every dose of vaccine possible, that should not be at the expense of missing an opportunity to vaccinate every eligible person when they are ready to get vaccinated.

Visit the DSHS COVID-19 Vaccine Disposal Guidelines for details on disposing waste:

<https://dshs.texas.gov/immunize/covid19/COVID19-Vaccine-Disposal-Guidelines.pdf>

COVID-19 VACCINE DISPOSAL GUIDELINES

The Centers for Disease Control and Prevention (CDC) states that COVID-19 vaccines should be treated as regulated medical waste in its disposal requirements from their [Identification, Disposal, and Reporting of COVID-19 Vaccine Wastage](#) notice. The CDC advises providers to waste COVID-19 vaccines in accordance with local regulations.

For guidance on reporting Moderna doses wasted, see the following guide:

<https://www.dshs.texas.gov/immunize/covid19/Moderna-Wastage-Table-Texas.pdf>

Moderna 10/14 COVID-19 Vaccine Wastage Guidance

For guidance on reporting waste in VAOS, see the following guide:

<https://www.dshs.texas.gov/immunize/covid19/Waste-in-VAOS.pdf>

COVID-19 Vaccine Waste Reporting Waste and Generating Waste Reports in VAOS October 25, 2021

For questions about reporting waste, call (833) 832-7068 (Option 2) or email COVID19VacShipments@dshs.Texas.gov.

Billing Codes

For questions related to billing, visit the Centers for Medicare and Medicaid Services (CMS) resource, which includes CPT codes for COVID-19 vaccines.

CMS COVID-19 Vaccines and Monoclonal Antibodies:
<https://www.cms.gov/medicare/medicare-part-b-drug-average-sales-price/covid-19-vaccines-and-monoclonal-antibodies>

The screenshot shows the CMS.gov website. The header includes the CMS.gov logo, a search bar, and navigation links for Medicare, Medicaid/CHIP, Medicare-Medicaid Coordination, Private Insurance, Innovation Center, Regulations & Guidance, Research, Statistics, Data & Systems, and Outreach & Education. The breadcrumb trail reads: Home > Medicare > Medicare Part B Drug Average Sales Price > COVID-19 Vaccines and Monoclonal Antibodies. The left sidebar lists links for Medicare Part B Drug Average Sales Price from 2022 down to 2005, along with Medicare Part B Drugs Regulations and COVID-19 Vaccines and Monoclonal Antibodies. The main content area is titled "COVID-19 Vaccines and Monoclonal Antibodies" and contains the following text: "Medicare Part B Payment for COVID-19 Vaccines and Certain Monoclonal Antibodies during the Public Health Emergency. CMS has released a [set of toolkits](#) for providers, states and insurers to help the health care system prepare and assist in swiftly administering these products once they become available. These resources are designed to increase the number of providers that can administer the products and ensure adequate reimbursement for administration in Medicare, while making it clear to private insurers and Medicaid programs their responsibility to cover these products at no charge to beneficiaries. This webpage provides the payment allowances and other related information for these products. For more information, review the [COVID-19 provider toolkit](#)." Below this text is a section titled "Payment Allowances and Effective Dates for COVID-19 Vaccines and their Administration During the Public Health Emergency:(DOS = Date of Service, TBD = To Be Determined)". This section contains a table with the following data:

CPT Code or HCPCS Code	CPT or HCPCS Short Descriptor	Labeler Name	Vaccine/Procedure Name	National Payment Allowance Effective for Claims with DOS on or after 03/15/2021	National Payment Allowance Effective for Claims with DOS through 03/14/2021	Effective Dates
91300	SARSCOV2 VAC 30MCG/0.3ML IM	Pfizer	Pfizer-BioNTech Covid-19 Vaccine	\$0.010 ^[1]	\$0.010 ^[1]	12/11/2020 – TBD
0001A	ADM SARSCOV2 30MCG/0.3ML 1ST	Pfizer	Pfizer-BioNTech Covid-19 Vaccine Administration – First Dose	\$40.000 ^[2]	\$16.940 ^[2]	12/11/2020 – TBD

Billing Resources

Additional billing information, including CPT Administration and Product Codes for the anticipated Moderna 2.5 mL Booster Only Product, can be found at the following AMA resources.

AMA COVID-19 CPT Vaccine and Immunization Codes:
<https://www.ama-assn.org/practice-management/cpt/covid-19-cpt-vaccine-and-immunization-codes>

AMA Find your COVID-19 Vaccine CPT Codes:
<https://www.ama-assn.org/find-covid-19-vaccine-codes>

The image displays two overlapping screenshots of the American Medical Association (AMA) website. The top screenshot shows the 'COVID-19 CPT® CODING AND GUIDANCE' page, which includes a search bar and a section titled 'Find your COVID-19 Vaccine CPT® Codes'. The bottom screenshot shows the 'COVID-19 CPT vaccine and immunization codes' page, which features a 'CONTENTS' section with links to 'Unique CPT codes approved for COVID-19 immunizations', 'Category I vaccine descriptors', 'Vaccine resources', and 'CPT® Assistant provides guidance for new codes'. Both screenshots show the AMA logo and navigation links like 'Join' and 'Renew'.

COVID-19 VAOS Job Aids

In the [COVID-19 VAOS Job Aid Catalog](#) you can find all the DSHS job aids you may need as a COVID-19 vaccine provider.

Vaccine Allocation & Order System (VAOS) – Learning Resources

COVID-19 Vaccine Job Aids

- [VAOS Tips & Tricks](#) (11/2/2021)
- [COVID-19 Vaccine Data Dashboard](#) (6/29/2021)
- [COVID-19 Vaccine Product Availability](#) (10/28/2021)
- [COVID-19 Vaccine Order Requests in VAOS](#) (10/25/2021)
- [Vaccine Transfers in VAOS](#) (10/25/2021)
- [VAOS Quick Start Guide](#) (11/19/2021)
- [COVID-19 Vaccine Shipments](#) (10/25/2021)
- [Reporting Waste in VAOS](#) (10/25/2021)
- [Moderna Wastage Table](#) (11/2/2021)
- [Generating Reports in VAOS](#) (6/18/2021)

COVID-19 Therapeutics Job Aids

- [COVID-19 Therapeutics Job Aid](#) (9/24/2021)
- [Therapeutics Enrollment Guide](#) (11/10/2021)

VAOS E-Learnings

- [COVID-19 Vaccine & Therapeutics VAOS Videos](#)
- [TVFC/ASN VAOS Videos](#)

TVFC/ASN Job Aids

- [VAOS Quick Start Guide](#) (11/19/2021)
- [Open Ordering](#) (10/20/2021)
- [Uploading Temperature Logs](#) (10/18/2021)
- [Vaccine Shipments](#) (10/18/2021)
- [Vaccine Transfers](#) (10/18/2021)
- [Entering Doses Administered](#) (10/18/2021)
- [Reconciling Physical Inventory](#) (10/18/2021)
- [Reporting Waste](#) (10/18/2021)
- [Generating Reports](#) (10/18/2021)

Updated 11/10/2021

COVID-19 Vaccine Fact Sheets

	Pfizer COVID-19 Vaccine (Ages 5-11, Orange Cap)	Pfizer COVID-19 Vaccine (Ages 12+, Purple Cap)	Pfizer COVID-19 Vaccine (Ages 12+, Gray Cap)	Moderna/Spikevax™ COVID-19 Vaccine	Janssen COVID-19 Vaccine
Fact Sheet for Healthcare Providers	https://www.fda.gov/media/153714/download Revised: 03 Jan 2022	https://www.fda.gov/media/153713/download Revised: 31 Jan 2022	https://www.fda.gov/media/153715/download Revised: 31 Jan 2022	https://www.fda.gov/media/144637/download Revised: 31 Jan 2022	https://www.fda.gov/media/146304/download Revised: 31 Jan 2022
Vaccine Information Fact Sheet for Recipients and Caregivers	https://www.fda.gov/media/153717/download Revised: 03 Jan 2022	https://www.fda.gov/media/153716/download Revised: 31 Jan 2022	https://www.fda.gov/media/153716/download Revised: 31 Jan 2022	https://www.fda.gov/media/144638/download Revised: 31 Jan 2022	https://www.fda.gov/media/146305/download Revised: 31 Jan 2022
Translations of Fact Sheets for Recipients and Caregivers	https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/comirnaty-and-pfizer-biontech-covid-19-vaccine#translated Revised: 23 Feb 2022	https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/comirnaty-and-pfizer-biontech-covid-19-vaccine#translated Revised: 23 Feb 2022	https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/comirnaty-and-pfizer-biontech-covid-19-vaccine#translated Revised: 23 Feb 2022	https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/spikevax-and-moderna-covid-19-vaccine#translated Revised: 16 Mar 2022	https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/janssen-covid-19-vaccine#translated Revised: 10 Mar 2022
Other				Important Prescribing Information: https://www.fda.gov/media/153354/download Spikevax package insert: https://www.fda.gov/media/155675/download	

Vaccine Manufacturer Resources



Medical Information

Phone: 800-438-1985

Email:

PfizerMedicalInformation@pfizer.com

Website: www.PfizerMedInfo.com



Medical Information

Phone: 866-663-3762

Email: MedInfo@modernatx.com

Temperature excursion related questions:

Email: excursions@modernatx.com



Medical Information

Phone: 800-565-4008

Temperature excursion related questions:

Email:

JSCCOVIDTEMPEXCURSION@its.jnj.com

Disclaimer

The information presented today is based on CDC's recent guidance and MAY change.

Tuesday, April 5th, 2022

Thank you!